A newly
developed antifungal, isavuconazole, is as effective as an existing drug,
voriconazole, against invasive mold disease in cancer patients with less
adverse effects, according to phase 3 clinical data presented at the 54th
Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious
disease meeting of the American Society for Microbiology.
Isavuconazole
is an investigational once-daily intravenous and oral broad-spectrum antifungal
being developed by Astellas and Basilea Pharmaceutica International Ltd. for
the treatment of life-threatening invasive fungal infections.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources